Literature DB >> 7660355

Structural evidence that the activation peptide is not released upon thrombin cleavage of factor XIII.

V C Yee1, L C Pedersen, P D Bishop, R E Stenkamp, D C Teller.   

Abstract

The three-dimensional structure of the recombinant human factor XIII a2 dimer after cleavage by thrombin has been determined by X-ray crystallography. Factor XIII zymogen was treated with bovine alpha-thrombin in the presence of 3 mM CaCl2, and the cleaved protein was crystallized from Tris buffered at pH 6.5 using ethanol as the precipitating agent. Refinement of the molecular model of thrombin-cleaved factor XIII against diffraction data from 10.0 to 2.5 A resolution has been carried out to give a crystallographic R factor of 18.2%. The structure of thrombin-cleaved factor XIII is remarkably similar to that of the zymogen: there are no large conformational changes in the protein and the 37 residue amino terminus activation peptide remains associated with the rest of the molecule. This work shows that the activation peptide, upon thrombin cleavage, has the same conformation and occupies the same position with respect to the rest of the molecule as it does in the zymogen structure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7660355     DOI: 10.1016/0049-3848(95)00072-y

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  14 in total

Review 1.  Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Future Microbiol       Date:  2010-08       Impact factor: 3.165

2.  Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function.

Authors:  Vytautas Ivaskevicius; Arijit Biswas; Carville Bevans; Verena Schroeder; Hans Peter Kohler; Hannelore Rott; Susan Halimeh; Petro E Petrides; Harald Lenk; Manuele Krause; Bruno Miterski; Ursula Harbrecht; Johannes Oldenburg
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

3.  Reversible activation of cellular factor XIII by calcium.

Authors:  Gunhild Klarskov Kristiansen; Mette Dahl Andersen
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

4.  Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.

Authors:  Prakash G Doiphode; Marina V Malovichko; Kelly Njine Mouapi; Muriel C Maurer
Journal:  Anal Biochem       Date:  2014-04-19       Impact factor: 3.365

5.  Activation of factor XIII is accompanied by a change in oligomerization state.

Authors:  Boris A Anokhin; Vilius Stribinskis; William L Dean; Muriel C Maurer
Journal:  FEBS J       Date:  2017-10-03       Impact factor: 5.542

6.  Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.

Authors:  Madhavi A Jadhav; Giulia Isetti; Toni A Trumbo; Muriel C Maurer
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

Review 7.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

8.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

9.  Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

Authors:  Anna D Protopopova; Andrea Ramirez; Dmitry V Klinov; Rustem I Litvinov; John W Weisel
Journal:  J Thromb Haemost       Date:  2019-03-14       Impact factor: 5.824

10.  Substrate specificity of microbial transglutaminase as revealed by three-dimensional docking simulation and mutagenesis.

Authors:  Uno Tagami; Nobuhisa Shimba; Mina Nakamura; Kei-Ichi Yokoyama; Ei-Ichiro Suzuki; Takatsugu Hirokawa
Journal:  Protein Eng Des Sel       Date:  2009-10-22       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.